• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Briefing Information for the July 29, 2009 Cardiovascular and Renal Drugs Advisory Committee

FDA

Disclaimer

 

Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).

FDA Briefing Material (pdf)

Errata (pdf)

 

***************

 

Boehringer Ingelheim Pharmaceuticals, Inc

Disclaimer

 

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

 

Micardis (Telmisartan) Briefing Material (pdf)